<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651621</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-AVH</org_study_id>
    <nct_id>NCT04651621</nct_id>
  </id_info>
  <brief_title>SMA Targeted Magnetic Stimulation Against Auditory Verbal Hallucinations</brief_title>
  <acronym>SMA-AVH</acronym>
  <official_title>SMA Targeted Magnetic Stimulation Against Auditory Verbal Hallucinations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Auditory verbal hallucinations (AVH) are prevalent among patients with psychiatric disorders.&#xD;
      Not only being highly stressful and functionally impairing, AVH often persist despite&#xD;
      treatment. Recent attempts to treat AVH with add-on repetitive transcranial magnetic&#xD;
      stimulation (rTMS) when targeting the temporoparietal junction (TPJ), a language node in the&#xD;
      brain, has gained limited success. The aim of this investigation is to reduce AVH with rTMS&#xD;
      using continous theta-burst stimulation over a novel target, the supplementary motor area&#xD;
      (SMA), in participants with frequent AVH, while also assessing potential neurophysiological&#xD;
      mechanisms underlying the symptom.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>First phase is a cross-over with two randomized blinded sessions with either verum cTBS or sham with wash-out, for each participant, and a second open feasibility treatment phase with 5 sessions/day over four days for participants with distressing auditory verbal hallucinations</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Identical sham coil, masked by an independent person.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude on EEG in speech-listen task</measure>
    <time_frame>5-30 minutes after intervention</time_frame>
    <description>Neurophysiological outcome of the blinded cross-over phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on The Psychotic Symptom Rating Scales (PSYRATS)</measure>
    <time_frame>1 day after completion of open treatment phase</time_frame>
    <description>Auditory Verbal Hallucination symptom interview, total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Finger tapping test</measure>
    <time_frame>5-30 minutes after intervention</time_frame>
    <description>Computerized version of the finger tapping test from The Halstead-Reitan Neuropsychological Test Battery, performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double step saccade-task</measure>
    <time_frame>20-60 minutes after intervention</time_frame>
    <description>Performance (Zimmermann et al Sci Rep, 2018).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting state functional magnetic resonance imaging (rsfMRI)</measure>
    <time_frame>1 day after completion of open treatment phase</time_frame>
    <description>Resting state SMA connectivity change as measured with fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance spectroscopy (MRS) over the SMA quantifying glutamate and gamma-aminobutyric acid (GABA) and other metabolites</measure>
    <time_frame>1 day after completion of open treatment phase</time_frame>
    <description>Prefrontal GABA and Glutamate concentration change as measured with a MEGA-PRESS magnetic resonance spectroscopy sequence following intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>1 day after completion of open treatment phase</time_frame>
    <description>Total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>App recorded ratings of auditory verbal hallucinations (AVH)</measure>
    <time_frame>From first day of open treatment phase, and through one week after completion of treatment</time_frame>
    <description>5 times a day randomized time points for app ratings of AVH</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Auditory Hallucination</condition>
  <arm_group>
    <arm_group_label>Open label active cTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four consecutive days with 40s cTBS, 100% MT over the SMA, five times a day with 50 minutes between stimulations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active cTBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One test session with 40s active cTBS, 100% MT, over the SMA in the initial double blind cross-over phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham cTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>One test session with 40s sham cTBS, 100% MT, over the SMA in the initial double blind cross-over phase with a special sham coil that diverts the magnetic field to be only superficial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous theta burst stimulation over the SMA</intervention_name>
    <description>Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.</description>
    <arm_group_label>Open label active cTBS</arm_group_label>
    <arm_group_label>active cTBS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham continuous theta burst stimulation over the SMA</intervention_name>
    <description>The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation</description>
    <arm_group_label>Sham cTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for the AVH group:&#xD;
&#xD;
          -  Reported AVH with a minimum frequency of at least daily occurrence, with onset more&#xD;
             than one month ago&#xD;
&#xD;
          -  Stable psychopharmacological treatment past month&#xD;
&#xD;
        Inclusion criteria for the non-AVH control group&#xD;
&#xD;
          -  Reporting no occurrences of AVH for the past year&#xD;
&#xD;
          -  Stable psychopharmacological treatment past month&#xD;
&#xD;
        Inclusion criteria for the healthy control group&#xD;
&#xD;
          -  No life-time occurrence of AVH&#xD;
&#xD;
          -  No history of psychiatric disorders as assessed with a Mini-International&#xD;
             Neuropsychiatric Interview (M.I.N.I.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ferromagnetic or electromagnetic implants that may pose a risk during magnetic&#xD;
             resonance imaging (MRI) and/or cTBS&#xD;
&#xD;
          -  A history of epilepsy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current substance use disorder or a history of alcohol use disorder as assessed with&#xD;
             Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification&#xD;
             Test (DUDIT), urine samples with test for illicit drugs and Phosphatidylethanol (PEth)&#xD;
&#xD;
          -  Daily benzodiazepine use&#xD;
&#xD;
          -  Factors that make the participant unlikely to be able to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Boden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Larsson</last_name>
    <phone>+46186112222</phone>
    <email>daniel.larsson@akademiska.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Persson, PhD</last_name>
    <phone>+46186112222</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of neuroscience, psychiatry, unit for Brain Stimulation and psychiatric clinical trials</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Boden, Ph.D, MD</last_name>
      <phone>+46 18 611 87 95</phone>
      <email>robert.boden@neuro.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Jonas Persson, Ph.D</last_name>
      <phone>+46 18 611 22 22</phone>
      <email>jonas.persson@neuro.uu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Cernvall, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elin Thörnblom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Steinholtz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Boden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallucinations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

